News AbbVie takes aim at Gilead and BMS with 8-week hep C treatme... Trial backs patient-friendly regime in tough to treat strain.
News FDA chief nominee Gottlieb reveals industry links Scott Gottlieb, president Donald Trump’s nomination for FDA commissioner has revealed his close links with pharma.
News Keytruda in new lymphoma use leads latest CHMP decisions MSD keeps pressure on BMS with EU classical Hodgkin lymphoma indication.
News NICE rejects Opdivo in blood cancer, asks for more data Merck's rival Keytruda gets new US indication.
News BMS appoints new science chief in fall-out from Opdivo setba... Bristol-Myers Squibb’s (BMS) chief scientific officer Francis Cuss is to step down following the company's huge lung cancer setback with Opdivo last year, to be replaced by former Massachus
News Icahn takes stake in BMS, adding to takeover speculation Activist investor's intervention adds to buzz surrounding BMS.
News Ipsen' Bylvay fluffs its lines in biliary atresia trial Ipsen's IBAT inhibitor Bylvay has failed a trial in biliary atresia, a rare and serious liver disease that affects babies and has limited treatments.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
